Peptide Graded

All peptides / Gut and weight

BPC-157

Synthetic pentadecapeptide (gastric-derived)

Also BPC157, BPC 157, Body Protection Compound 157, Body Protective Compound-157, Pentadecapeptide BPC 157, PL 14736

Evidence
CAnimal and cell studies
FDA status
Not approvedas of 2026-10-27
Route
Several routes
Studies cited
1 human35 animal or cell

Sold for

BPC-157 is sold as a healing peptide for tendons, ligaments, muscle and gut, taken by injection or orally, and is one of the most popular compounds in the grey-market peptide trade.

Studies say

Dozens of rat studies, nearly all from one laboratory, show faster tendon, ligament and gut healing, but the only human data are a 12-patient uncontrolled series, so nothing is established in people (grade C).

Why grade C. A 2025 systematic review found 36 studies of BPC-157 for musculoskeletal injury: 35 preclinical, almost all in rats from one Zagreb research group, and one retrospective human series of 12 patients with knee pain. No randomized or controlled human trial has been published, so the healing claims rest on animal data (grade C). 413

FDA. BPC-157 is not approved by the FDA for any use and is sold as a research chemical. The FDA put it in Category 2 of substances nominated for compounding in 2023 over safety concerns; the nominators later withdrew it, and the agency's Category 2 page now lists it as nominated but withdrawn. In July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend adding it to the 503A bulks list, but the FDA has not proposed a rule to do so, so it still cannot be lawfully compounded.

Written from 14 cited sources. Last refreshed 2026-10-27. Not physician reviewed.

Evidence checklist

  • Randomised controlled trial No randomized human trialno
  • Human study over 100 people Only a 12-patient human seriesno
  • More than one research group Nearly all work from one Zagreb groupno
  • Clinical outcomes, not surrogate markers No human clinical outcomesno
  • Human safety data beyond case reports No human safety datano

Drawn from the cited studies below. A dash means the sources give no information.

What it is

BPC-157 is a synthetic 15-amino-acid peptide (a pentadecapeptide, sequence GEPPPGKPADDAGLV) that its developers describe as a fragment of a protective protein found in human gastric juice. 'BPC' stands for body protection compound. Nearly all the research comes from Predrag Sikiric's group at the University of Zagreb, which has published on it since the early 1990s. 123

The compound was licensed to the Croatian company Pliva under the codes PL 14736 and PLD-116 and reached early clinical trials for inflammatory bowel disease around 2000, but no results from those trials were published and the programme went quiet. A trial listed on ClinicalTrials.gov (NCT02637284) has likewise produced no published results. BPC-157 now circulates as a research chemical sold by online vendors and injected or swallowed by athletes and biohackers. 51112

How it works

The Zagreb group describes BPC-157 as a 'cytoprotective' agent, a term from gastric physiology for substances that protect the stomach lining from injury, and proposes that the same protection extends to tendon, muscle, nerve, blood vessels and other tissues. 210

In animal and cell studies the peptide increased expression of growth hormone receptors on tendon cells, activated signalling pathways involved in cell growth and new blood vessel formation (angiogenesis), raised nitric oxide availability and reduced inflammatory cytokines. In cultured tendon cells it did not stimulate growth by itself but reversed the growth-inhibiting effect of a toxic aldehyde. These are mechanistic observations from laboratory systems; none has been confirmed in human tissue. 1113

What human research shows

The 2025 systematic review from the Hospital for Special Surgery searched the literature to June 2024 and found 36 eligible studies on musculoskeletal effects: 35 preclinical and one clinical. The clinical study was a retrospective report of 12 patients given BPC-157 injections into the knee for unspecified chronic knee pain, of whom 7 reported relief lasting more than six months. There was no control group, no blinding and no objective outcome measure. 413

No randomized trial, controlled trial or prospective cohort of BPC-157 in humans has been published for any indication. The 2026 STAT News profile of Sikiric records that he acknowledges the absence of human trials and attributes it to lack of funding. 3

StudyModelFinding
Staresinic 2003, J Orthop ResRats with transected Achilles tendon, plus cultured tendon cellsBPC-157 improved tendon strength, elasticity, function and histology versus saline, and reversed aldehyde-induced growth inhibition in cultured tendocytes. 11
HSS systematic review, 2025Systematic review: 35 preclinical studies and 1 clinical study (n=12, retrospective)Consistent benefit in rodent models of muscle, tendon, ligament and bone injury; human evidence limited to 7 of 12 knee-pain patients reporting relief; no clinical safety data. 13
Cytoprotection review, 2019Narrative review of animal studiesDescribes BPC-157's proposed role as a cytoprotective mediator across organ systems, based on rat experiments. 10
FDA 503A category list, 2023Regulatory review of nominated compounding substancesBPC-157 placed in Category 2 (may present significant safety risks) for lack of safety data; nominators later withdrew. 7

Safety

Preclinical safety studies reviewed in 2025 found no adverse effects across several organ systems in rodents, and the peptide has a half-life under 30 minutes, is metabolised in the liver and cleared by the kidneys. The same review found no clinical safety data at all. 13

The practical risks are therefore those of an unregulated product: unknown purity, possible contamination and incorrect labelling of vials sold online. The FDA's 2023 decision placed BPC-157 in Category 2 citing a lack of safety data and concerns about immunogenicity and peptide impurities. Because BPC-157 promotes blood vessel growth in animal models, a theoretical concern exists about feeding tumours; no study has examined it. WADA prohibits BPC-157 at all times under its non-approved substances class, and USADA has warned athletes about it. 7914

Questions for your clinician

  • Is there any controlled human trial for the use I have in mind?
  • How can I tell what is actually in a vial sold online?
  • Are there treatments with trial evidence for my tendon or gut problem?

Questions people ask

Where does the FDA stand on BPC-157?

No. It is not approved for any use, and in 2023 the FDA put it in Category 2 for compounding, which bars pharmacies from making it. An advisory committee recommended in July 2026 that it be added to the compounding list, but the FDA has not acted on that recommendation. 678

Can you lawfully buy or sell BPC-157 in the US?

It is sold as a research chemical 'not for human consumption', which is how vendors avoid drug law. Marketing it for human use without approval violates the Food, Drug and Cosmetic Act, and licensed pharmacies cannot compound it. Possession is not itself a crime. 67

Can a doctor prescribe BPC-157?

A prescription cannot be filled lawfully because no approved product exists and compounding is not permitted under the current Category 2 status. Clinics that supply it are operating outside FDA rules. 78

How do BPC-157 and TB-500 differ from each other?

Both are sold for injury recovery and both are unapproved. BPC-157 is a 15-amino-acid gastric-derived peptide studied mostly in rat tendon and gut models. TB-500 is a fragment of thymosin beta-4, a natural protein involved in cell migration and wound healing, with its own set of animal studies and a few human trials of the parent protein. 113

Is BPC-157 banned in sport?

Yes. WADA lists it under S0, non-approved substances, which are prohibited at all times, and USADA has issued a specific warning about it. 914

Citations

  1. International Journal of Molecular Sciences 2026: BPC 157 pentadecapeptide review doi.org
  2. Pharmaceuticals 2025: BPC 157 as a cytoprotective agent doi.org
  3. STAT News 2026: BPC-157 researcher Predrag Sikiric addresses skeptics statnews.com
  4. HSS Journal 2025: emerging use of BPC-157 in orthopaedic sports medicine, systematic review (DOI) doi.org
  5. ClinicalTrials.gov: NCT02637284 clinicaltrials.gov
  6. FDA: bulk drug substances used in compounding under section 503A fda.gov
  7. FDA: bulk drug substances that may present significant safety risks in compounding fda.gov
  8. STAT News 2026: FDA peptide compounding panel votes statnews.com
  9. USADA: BPC-157, a prohibited peptide usada.org
  10. Cell and Tissue Research 2019: BPC 157 cytoprotection review doi.org
  11. Staresinic 2003, J Orthop Res: BPC 157 accelerates healing of transected rat Achilles tendon pubmed.ncbi.nlm.nih.gov
  12. ClinicalTrials.gov registry clinicaltrials.gov
  13. HSS Journal 2025: emerging use of BPC-157 in orthopaedic sports medicine, systematic review pubmed.ncbi.nlm.nih.gov
  14. WADA: Prohibited List wada-ama.org

Related